Phase 1 open-label dose escalation study of the dual SYK/JAK inhibitor cerdulatinib (PRT062070) in patients with relapsed/refractory B-cell malignancies: Safety profile and clinical activity Meeting Abstract
| Authors: | Flinn, I.; Hamlin, P. A.; Strickland, D. K.; Pandey, A.; Birrell, M.; Coffey, G.; Leeds, J.; Curnutte, J. T.; Burger, J. A.; Wagner-Johnston, N. D.; Patel, M. R. |
| Abstract Title: | Phase 1 open-label dose escalation study of the dual SYK/JAK inhibitor cerdulatinib (PRT062070) in patients with relapsed/refractory B-cell malignancies: Safety profile and clinical activity |
| Meeting Title: | 51st Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 33 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2015 May 29-Jun 2 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2015-05-20 |
| Language: | English |
| ACCESSION: | WOS:000358036901843 |
| PROVIDER: | wos |
| DOI: | 10.1200/jco.2015.33.15_suppl.8531 |
| Notes: | Meeting Abstract: 8531 -- Source: Wos |
